前列腺癌患者PD-1水平与肿瘤分期的关系

Analysis of the relationship between PD-1 levels and tumor stages in patients with prostate cancer

目的分析程序性死亡受体1(PD-1)在前列腺癌(PCa)患者中的表达及与肿瘤分期的关系。方法选取2018年1月至2021年1月在本院收治的150例PCa患者的术后组织标本作为研究对象(PCa组),并选取同期住院治疗的130例行手术治疗的良性前列腺增生(BPH)患者术后组织标本作为BPH组。采用免疫组化、ELISA法检测两组患者的PD-1表达水平,根据不同PD-1重组蛋白浓度将PCa细胞分为对照组、50μg/L组和100μg/L组,分别应用划痕实验及Transwell小室实验检测PC3细胞的迁移形态。结果PCa组的PD-1表达水平高于BPH组,差异有统计学意义(P=0.001)。Ⅰ期PCa患者的PD-1表达水平为(13.60±6.31)pg/mL,Ⅱ期PCa患者为(16.51±4.88)pg/mL,Ⅲ期PCa患者为(21.68±5.13)pg/mL,Ⅳ期PCa患者为(29.50±4.78)pg/mL,随着患者肿瘤分期进展,PD-1表达水平逐渐升高(均P<0.05)。PCa组中Gleason评分为7~10分患者的PD-1表达水平高于Gleason评分为1~6分患者,差异有统计学意义(P<0.001)。PC3细胞迁移细胞数随着培养时间的延长,细胞愈合的程度越强(P<0.05)。Transwell小室实验结果显示,50μg/L组和100μg/L组的细胞迁移距离均长于对照组(均P<0.05)。结论PD-1可作为PCa疾病进展和预后评估的生物标志物,PD-1靶向治疗可能是治疗PCa的潜在方法。

ObjectiveTo analyze the relationship between programmed death 1(PD-1)expression in prostate cancer(PCa)patients and tumor stage.MethodsPostoperative tissue specimens of 150 PCa patients admitted to our hospital from January 2018 to January 2021 were selected as the study object(PCa group),and postoperative tissue specimens of 130 hospitalized patients with benign prostate hyperplasia(BPH)undergoing surgical treatment during the same period were selected as the BPH group.PD-1 expression was detected by immunohistochemistry and ELISA.PCa cells were divided into control group,50μg/L group and 100μg/L group.The migration morphology of PC3 cells was detected by scratch test and Transwell laboratory test,respectively.ResultsPD-1 expression level in PCa group was higher than that in BPH group,and the difference was statistically significant(P=0.001).The expression level of PD-1 was(13.60±6.31)pg/mL in patients with stageⅠPCa,(16.51±4.88)pg/mL in patients with stageⅡPCa,(21.68±5.13)pg/mL in patients with stageⅢPCa,and(29.50±4.78)pg/mL in patients with stageⅣPCa.The expression level of PD-1 increased gradually with the progression of tumor stage(all P<0.05).The expression level of PD-1 in patients with Gleason score 7-10 in PCa group was higher than those with Gleason score 1-6,and the difference was statistically significant(P<0.001).The number of PC3 cells migrated with the extensionof culture time,the degree of cell healing was stronger(P<0.05).The results of Transwell laboratory experiment showed that the migration distance of 50μg/L group and 100μg/L group was longer than that of control group(all P<0.05).ConclusionsThe clinical value of PD-1 as a biomarker for PC progression and prognosis assessment needs further study.PD-1 targeting may be a potential target for the treatment of human prostate cancer.